Clinical Trials Logo

Filter by:
NCT ID: NCT05813561 Completed - Reflux Esophagitis Clinical Trials

The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis

Start date: December 30, 2021
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy, safety, and cost-effectiveness of DWP14012 40 mg compared to esomeprazole magnesium enteric-coated tablets for the treatment of reflux esophagitis.

NCT ID: NCT05813522 Enrolling by invitation - Clinical trials for Non Small Cell Lung Cancer

Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC

Start date: April 15, 2022
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate the clinical efficacy and safety of Furmonertinib in EGFR mutated NSCLC patients with leptomeningeal metastasis and to explore the feasibility of CSF ctDNA detection for efficacy evaluation. Participants will be treated with 160mg Furmonertinib daily and tumor evaluation will be performed every 6-8 weeks. The participants' blood and cerebrospinal fluid samples will be collected three times during the study for ctDNA detection.

NCT ID: NCT05813509 Recruiting - Ovarian Cancer Clinical Trials

Individualized Precision Treatment Based on Ovarian Cancer Organoid Model

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

The research purpose of this study is to use organoid cultured from patients' own ovarian cancer tissues as models, screen potential clinical therapeutic drugs (such as paclitaxel, gemcitabine, etc.) in vitro, formulate individualized drug treatment plans for individual patient, and evaluate the clinical application value of organ like drug sensitivity technology.

NCT ID: NCT05813015 Recruiting - Chemotherapy Effect Clinical Trials

Study of Comparing of With and Without Sequential Therapy of S-1

Start date: January 28, 2023
Phase: Phase 3
Study type: Interventional

The goal of this single arm clinical trial is to learn about sequential S-1 adjuvant therapy in patient wich locally advanced gastric cancer. The main question it aims to answer is: • The efficacy and safety of S-1 adjuvant therapy, following D2 radical surgery and DS(Docetaxel + S-1) adjuvant chemotherapy. All patients with locally advanced gastric cancer will received D2 radical surgery, 6 cycles of DS chemotherapy, and sequential S-1 chemotherapy up to 1 year postoperation.

NCT ID: NCT05812677 Recruiting - Cervical Cancer Clinical Trials

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and Endometrial Cancer

Start date: February 6, 2023
Phase: Early Phase 1
Study type: Interventional

20 participants are expected to be enrolled for this open,Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with relapsed/refractory Cervical and Endometrial Cancer.

NCT ID: NCT05812612 Recruiting - COVID-19 Infection Clinical Trials

UDCA in the Treatment of COVID-19 Infection and Its Clinical Prognosis in Patients With Autoimmune Liver Disease

Start date: January 30, 2023
Phase:
Study type: Observational

This is a two-way (retrospective+prospective) cohort study of patients with primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH) infected with COVID-19. Enrolled PBC and AIH patients in clinical diagnosis and treatment at Beijing Ditan Hospital affiliated with Capital Medical University from January 2021 to December 2023. After enrollment, collect the demography data of patients, the treatment information of PBC and AIH patients, the use of ursodeoxycholic acid (UDCA) and immunosuppressants, COVID-19 vaccination, COVID-19 infection and incidence, clinical symptoms, clinical biochemistry, liver imaging, lung imaging, COVID-19 nucleic acid, COVID-19 antibody, and the incidence and treatment information of COVID-19 from January 2022 to pre enrollment. After enrollment, the corresponding treatment and clinical observation of PBC and AIH were continued, and the occurrence and incidence of COVID-19 infection were observed. For patients with COVID-19 infection during the prospective observation period, COVID-19 infection, onset and treatment were observed, including clinical symptoms, signs, heart, lung imaging, COVID-19, clinical biochemistry, disease degree, virus negative, hospital stay and prognosis. To compare the difference of COVID-19 infection rate, disease severity, clinical biochemical indicators, hospital stay and prognosis between UDCA treated and non UDCA treated patients, and to study the impact of UDCA on the occurrence, incidence and prognosis of COVID-19 infection.

NCT ID: NCT05812495 Recruiting - Clinical trials for Epiphora Due to Insufficient Drainage, Right Side

Minimally Invasive Intrathoracic Esophagogastric Side to Side Anastomosis vs. End to Side Anastomosis

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

On the basis of minimally invasive Ivor Lewis operation for the treatment of lower thoracic esophageal cancer or esophageal gastric junction cancer, the purpose of this study is to compare the probability of anastomotic leakage and stenosis after esophagogastric side to side anastomosis and esophagogastric end to side anastomosis, combined with the probability of complications, quality of life and survival rate of patients after the two anastomotic methods, To explore which anastomotic method is better than the worse for patients with lower thoracic esophageal cancer or cancer at the junction of esophagus and stomach. This study explored a minimally invasive anastomotic method with lower incidence of complications and higher quality of life for patients during Ivor Lewis surgery, which can increase the clinical benefits of patients, improve the quality of life, and extend the survival period, and has important clinical value.

NCT ID: NCT05812482 Recruiting - Clinical trials for Urethral Stricture Less Than 2 cm

Treatment of Urethral Stricture With Urethral Drug Ball

Start date: March 31, 2022
Phase: N/A
Study type: Interventional

To evaluate the safety and efficacy of urethral drug balloon catheter in the treatment of urethral stricture.

NCT ID: NCT05812430 Recruiting - Clinical trials for Advanced Biliary Tract Cancer

Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer

Start date: April 10, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of anlotinib plus TQB2450 combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer

NCT ID: NCT05812326 Completed - Clinical trials for Advanced Breast Cancer

PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer

Start date: May 17, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This exploratory clinical study aims to assess the safety and preliminary efficacy of an immunotherapy using PD-1 knockout anti-MUC1 CAR-T cells in the treatment of advanced MUC1-positive breast cancer